Biocartis Group NV: Disclosure of a transparency notification

 

Biocartis Group NV (the 'Company' or 'Biocartis'), an innovative molecular diagnostics company (Euronext Brussels: BCART), announces today in accordance with Article 14, paragraph 1 of the Belgian Act of 2 May 2007 on the disclosure of major shareholdings in issuers whose shares are admitted to trading on a regulated market (the 'Belgian Transparency Act'), that it received a transparency notification dated 1 June 2017 (the 'Notification'), indicating that Rudi Pauwels (through entities controlled by him) now holds 1.4% (rounded) of the voting rights in Biocartis. As a result, the lowest notification threshold of 3% has been crossed.

The Notification contains the following information:

 

  • Reason for the Notification: downward crossing of the lowest threshold.
     
  • Notification by: a parent undertaking or a controlling person.
     
  • Persons subject to the notification requirement: Rudi Pauwels; Benaruca S.A., 4 rue du Fort Wallis, 2714 Luxembourg; Benaruca Life Science Investments S.à r.l., 4 rue du Fort Wallis, 2714 Luxembourg.
     
  • Transaction date: 31 May 2017.
     
  • Threshold that is crossed: 3%.
     
  • Denominator: 44,648,105.
     
  • Details of the Notification: Benaruca S.A. holds 27,930 voting securities, Benaruca Life Science Investments S.à r.l. holds 614,523 voting securities.
     
  • Chain of controlled undertakings through which the holding is effectively held: Rudi Pauwels controls Benaruca S.A., which in turn controls Benaruca Life Science Investments S.à r.l.
     
  • Additional information: Benaruca Life Science Investments S.à r.l. was incorporated on 30 May 2017. On such date, Benaruca S.A. contributed 2,479,808 shares of Biocartis Group NV into Benaruca Life Science Investments S.à r.l.

 

The Notification is available here on the website of the Company.

 

Pursuant to the Belgian Transparency Act and the articles of association of the Company, a notification to the Company and the Belgian Financial Services and Markets Authority ('FSMA') is required by all natural and legal persons in each case where the percentage of voting rights in the Company held by such persons reaches, exceeds or falls below the threshold of 3%, 5%, 10%, and every subsequent multiple of 5%, of the total number of voting rights in the Company.

Note

Biocartis (Euronext Brussels: BCART) is an innovative molecular diagnostics (MDx) company providing next generation diagnostic solutions aimed at improving clinical practice for the benefit of patients, clinicians, payers and industry. Biocartis' proprietary MDx Idylla(TM) platform is a fully automated sample-to-result, real-time PCR (Polymerase Chain Reaction) system that offers accurate, highly reliable molecular information from virtually any biological sample in virtually any setting. Biocartis launched the Idylla(TM) platform in September 2014. Biocartis is developing and marketing a rapidly expanding test menu addressing key unmet clinical needs in oncology and infectious diseases. These areas represent respectively the fastest growing and largest segments of the MDx market worldwide. Today, Biocartis offers nine oncology tests and two infectious disease tests. More information: www.biocartis.com. Press Photo Library available here. Follow us on Twitter: @Biocartis_.

 

 

Interested in a regular update of the Life Sciences and biotech sector in Flanders?